<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34397718</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>30</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Relationship between statins and the risk of amyotrophic lateral sclerosis: A PRISMA-compliant meta-analysis.</ArticleTitle><Pagination><StartPage>e26751</StartPage><MedlinePgn>e26751</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e26751</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000026751</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Previous studies on overlapping surveillance databases have suggested that statin use was associated with the development of amyotrophic lateral sclerosis (ALS)-like syndrome. However, the association between statin use and ALS incidence has not been clearly elucidated. To further explore this issue, we performed a systemic review and meta-analysis of all available clinical studies on the association between statin use and ALS incidence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive database search on PubMed, Embase, Cochrane Library, and SCOPUS was conducted. We included studies up to January 31, 2020 that fulfilled our inclusion and exclusion criteria. Statin use between the ALS and control groups was collected for the meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three case-control studies and 1 cohort study, that related the risk of ALS to statin use, satisfied the inclusion criteria for the meta-analysis. There was no statistically significant difference in statin use between the ALS and control groups (odds ratio, 0.75 [95% confidence interval, 0.53-1.08]).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">No definite association was found between statin use and the development of ALS. Further large-scale prospective randomized control studies are necessary to draw definite conclusions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Min Cheol</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Sang Gyu</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, College of Medicine, Daegu Catholic University, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin-Sung</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Donghwi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NRF-2019M3E5D1A02068106</GrantID><Agency>National Research Foundation of Korea grand funded by the Korean government</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>16</Day><Hour>12</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34397718</ArticleId><ArticleId IdType="pmc">PMC8322535</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000026751</ArticleId><ArticleId IdType="pii">00005792-202107300-00039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688&#x2013;700. doi:10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh JH, Park D, Kim IS, Kim H, Shin CM, Ryu JS. Feasibility of high-resolution manometry for decision of feeding methods in patients with amyotrophic lateral sclerosis. Medicine (Baltimore) 2019;98:e15781.doi:10.1097/MD.0000000000015781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6571283</ArticleId><ArticleId IdType="pubmed">31169677</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D, Park JS. Terminal latency abnormality in amyotrophic lateral sclerosis without split hand syndrome. Neurol Sci 2017;38:775&#x2013;81. doi:10.1007/s10072-017-2842-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28188450</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D, Lee GJ, Kim HY, Ryu JS. Different characteristics of ventilator application between tracheostomy- and noninvasive positive pressure ventilation patients with amyotrophic lateral sclerosis. Medicine (Baltimore) 2017;96:e6251.doi:10.1097/MD.0000000000006251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5348174</ArticleId><ArticleId IdType="pubmed">28272226</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Ryan Price T, Geiger JT, Chi&#xf2; A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun 2016;7:12408.doi:10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. . Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81:385&#x2013;90. doi:10.1136/jnnp.2009.183525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, et al. . Prevalence of amyotrophic lateral sclerosis &#x2013; United States, 2015. MMWR Morb Mortal Wkly Rep 2018;67:1285&#x2013;9. doi:10.15585/mmwr.mm6746a1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson C, Kilborn S, Oskoui M, Genge A. Incidence and prevalence of amyotrophic lateral sclerosis in Canada: a systematic review of the literature. Neuroepidemiology 2009;33:79&#x2013;88. doi:10.1159/000222089.</Citation><ArticleIdList><ArticleId IdType="pubmed">19494548</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D, Kwak SG, Park JS, Choo YJ, Chang MC. Can therapeutic exercise slow down progressive functional decline in patients with amyotrophic lateral sclerosis? A meta-analysis. Front Neurol 2020;11:853.doi:10.3389/fneur.2020.00853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438585</ArticleId><ArticleId IdType="pubmed">32903629</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Kwak SG, Park JS, Park D. The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis. Sci Rep 2020;10:14759.doi:10.1038/s41598-020-71813-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7479139</ArticleId><ArticleId IdType="pubmed">32901053</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesen JA, Rodwell VW. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol 2004;5:248.doi:10.1186/gb-2004-5-11-248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545772</ArticleId><ArticleId IdType="pubmed">15535874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf 2012;3:133&#x2013;44. doi:10.1177/2042098612439884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110822</ArticleId><ArticleId IdType="pubmed">25083232</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373&#x2013;418. doi:10.2165/0129784-200808060-00004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849981</ArticleId><ArticleId IdType="pubmed">19159124</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman CB, Preiss D, Tobert JA, et al. . Statin aafety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019;39:e38&#x2013;81. doi:10.1161/ATV.0000000000000073.</Citation><ArticleIdList><ArticleId IdType="pubmed">30580575</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf 2007;30:515&#x2013;25. doi:10.2165/00002018-200730060-00005.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536877</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman E, Szarfman A, Wyeth J, et al. . An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf 2008;17:1068&#x2013;76. doi:10.1002/pds.1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">18821724</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, et al. . Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008;70:1004&#x2013;9. doi:10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshii Y, Hadano S, Otomo A, Kawabe K, Ikeda K, Iwasaki Y. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 2010;74:2027.author reply 2027-2028, doi:10. 1212/WNL. 0b013e3181e03bbe.</Citation><ArticleIdList><ArticleId IdType="pubmed">20548050</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto K, Yoshii Y, Ikeda K. Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice. Amyotroph Lateral Scler 2009;10:405&#x2013;9. doi:10.3109/17482960902870993.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Yan J, Chen X, et al. . Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011;230:27&#x2013;34. doi:10.1016/j.expneurol.2010.04.006.</Citation><ArticleIdList><ArticleId IdType="pubmed">20406638</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll CB, Wyse RKH. Simvastatin as a potential disease-modifying therapy for patients with Parkinson's disease: rationale for clinical trial, and current progress. J Parkinson Dis 2017;7:545&#x2013;68. doi:10.3233/JPD-171203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5676977</ArticleId><ArticleId IdType="pubmed">29036837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Sheng L, Shang H. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:241&#x2013;5. doi:10.3109/21678421.2012.732078.</Citation><ArticleIdList><ArticleId IdType="pubmed">23134508</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson L, Tanner VDES, Albers C, et al. . Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neuroepidemiology 2009;33:77.</Citation></Reference><Reference><Citation>Lo CK, Mertz D, Loeb M. Newcastle&#x2013;Ottawa Scale: comparing reviewers&#x2019; to authors&#x2019; assessments. BMC Med Res Methodol 2014;14:45.doi:10.1186/1471-2288-14-45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021422</ArticleId><ArticleId IdType="pubmed">24690082</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, et al. . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10:ED000142.doi:10.1002/14651858.ED000142.</Citation><ArticleIdList><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes 2010;3:413&#x2013;7. doi:10.1161/CIRCOUTCOMES.110.936278.</Citation><ArticleIdList><ArticleId IdType="pubmed">20530788</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M, van Doormaal PT, Visser AE, et al. . Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 2014;261:1949&#x2013;56. doi:10.1007/s00415-014-7445-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">25059395</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:538&#x2013;46. doi:10.1080/21678421.2018.1511731.</Citation><ArticleIdList><ArticleId IdType="pubmed">31112080</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraj R, Kumarasamy C, Madhav MR, et al. . Comment on "Systematic review and meta-analysis of diagnostic accuracy of miRNAs in patients with pancreatic cancer&#x201d;. Dis Markers 2018;2018:6904569.doi:10.1155/2018/6904569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6217755</ArticleId><ArticleId IdType="pubmed">30425753</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaraj R, Kumarasamy C. Comment on &#x201c;Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis&#x201d;. Br J Cancer 2018;118:e11.doi:10.1038/bjc.2017.482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846075</ArticleId><ArticleId IdType="pubmed">29449675</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629&#x2013;34. doi:10.1136/bmj.315.7109.629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evolution 2005;59:464&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15807430</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JM, Kim SY, Park D, Park JS. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci 2020;41:119&#x2013;23. doi:10.1007/s10072-019-04055-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223963</ArticleId><ArticleId IdType="pubmed">31471712</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733&#x2013;48. doi:10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D. Application of different ventilator modes in patients with amyotrophic lateral sclerosis according to certain clinical situations: a case report. Medicine (Baltimore) 2017;96:e7899.doi:10.1097/MD.0000000000007899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5572032</ArticleId><ArticleId IdType="pubmed">28834910</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JS, Park D. The terminal latency of the phrenic nerve correlates with respiratory symptoms in amyotrophic lateral sclerosis. Clin Neurophysiol 2017;128:1625&#x2013;8. doi:10.1016/j.clinph.2017.06.039.</Citation><ArticleIdList><ArticleId IdType="pubmed">28719826</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Lang AG, Buchner A. G&#x2217;Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175&#x2013;91. doi:10.3758/bf03193146.</Citation><ArticleIdList><ArticleId IdType="pubmed">17695343</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Liao Y, Wang J, et al. . The antineuroinflammatory effect of simvastatin on lipopolysaccharide activated microglial cells. Evid Based Complement Alternat Med 2018;2018:9691085.doi:10.1155/2018/9691085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247388</ArticleId><ArticleId IdType="pubmed">30524484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>